Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Arch Pathol Lab Med ; 146(6): 701-709, 2022 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-34559875

RESUMO

CONTEXT.­: The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society of Clinical Oncology/College of American Pathologists guideline, cases wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an average HER2 copy number of less than 4.0 were considered in situ hybridization (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 2 and are no longer considered eligible for anti-HER2 therapy when the corresponding HER2 immunohistochemistry result is 0, 1+, or 2+. OBJECTIVE.­: To assess the clinical, pathologic, and treatment aspects of patients with ISH Group 2 results. DESIGN.­: We retrospectively reviewed HER2 FISH results at our center between January 2012 and December 2014 and identified and characterized cases with ISH Group 2 results. RESULTS.­: Thirty-nine cases with ISH Group 2 results from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 therapy. Patients treated with HER2-targeted therapy were less likely to have hormone receptor-positive tumors, compared with patients without anti-HER2 treatment, though not significantly (P = .30). The only significant difference between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < .001). Overall, clinical outcome was similar between the 2 groups (P > .99). CONCLUSIONS.­: This retrospective study with median follow-up of at least 6 years shows patients with ISH Group 2 tumors had similar clinical outcomes, irrespective of HER2-targeted therapy. Further analysis in the prospective setting would provide valuable data that would potentially inform clinical decision making.


Assuntos
Neoplasias da Mama , Variações do Número de Cópias de DNA , Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/patologia , Centrômero/genética , Cromossomos Humanos Par 17/genética , Feminino , Humanos , Hibridização in Situ Fluorescente/métodos , Oncologia , Patologistas , Estudos Prospectivos , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Estudos Retrospectivos
2.
Clin Breast Cancer ; 18(5): e1031-e1036, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-29625911

RESUMO

BACKGROUND: Women with breast imaging often seek second opinions at tertiary care centers. Our study measures the frequency of discrepancy between initial and second opinion breast imaging recommendations and evaluates the impact on patient management. MATERIALS AND METHODS: A retrospective chart review was conducted on 504 consecutive patients with second opinion breast radiology interpretations performed by 6 sub-specialized breast radiologists at a dedicated cancer center from January 1, 2014 through September 1, 2014. Outside imaging reports were compared with second opinion reports to categorize discrepancies. Interpretations were considered discrepant in cases with Breast Imaging Reporting and Data System (BI-RADS) category changes, recommendation for additional imaging, or identification of previously undiagnosed additional extent of disease greater than 5 cm. The frequencies of discrepancy, alterations in surgical management, and incremental cancer detection were measured. Statistical analysis of associated factors was performed with the Fisher exact test, with a P-value < .05 considered significant. RESULTS: Second opinion evaluation discrepancies were seen in 287 (57%) patients and resulted in percutaneous image-guided biopsies in 92 (18%). Forty-five additional sites of cancer were biopsy-detected in 41 (8%) patients, including 20 breast malignancies and 25 axillary metastases. Another 9 biopsies yielded high-risk pathology. Second opinion interpretations altered surgical management in 66 (13%) patients. Factors associated with increased discrepancy frequency were cancer diagnosis at presentation (P = .004), dense breasts (P = .005), and the absence of prior studies for comparison (P = .007). CONCLUSION: Although additional imaging and resources are required, second opinion radiology review by subspecialized breast radiologists increases cancer detection and results in clinically relevant changes in patient management.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Mama/diagnóstico por imagem , Encaminhamento e Consulta/estatística & dados numéricos , Axila , Mama/patologia , Neoplasias da Mama/patologia , Feminino , Humanos , Linfonodos/diagnóstico por imagem , Linfonodos/patologia , Imageamento por Ressonância Magnética , Variações Dependentes do Observador , Radiologistas , Estudos Retrospectivos , Fatores de Risco , Centros de Atenção Terciária , Tomografia Computadorizada por Raios X
3.
Radiol Case Rep ; 12(2): 219-222, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28491155

RESUMO

Angiomatosis of the breast is an extremely rare, benign vascular lesion. This is a diagnostic challenge, given the limited number of cases reported in the literature. Additionally, due to similar features of the more common malignant vascular tumor, angiosarcoma familiarity with angiomatosis in the differential diagnosis is important. We present a case of angiomatosis of the breast in a 28-year-old female. The lesion presented as an incidental enhancing mass on computed tomography scan initially and subsequent mammogram and ultrasound studies did not show a correlate. Next, magnetic resonance imaging demonstrated an enhancing correlate for which magnetic resonance imaging biopsy and subsequent excisional biopsy demonstrated angiomatosis of the breast.

4.
Curr Oncol Rep ; 14(4): 350-8, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22639107

RESUMO

Thymoma is a unique neoplasm of the anterior mediastinum that is frequently associated with indolent growth and a variety of paraneoplastic syndromes. One third of cases are detected during the evaluation of myasthenia gravis. Classification systems of thymoma have limited ability in accurately predicting prognosis and course of disease. Thus, staging is the only way to predict clinical behavior. Encapsulated tumors that are surgically resected carry the best prognosis. Adjuvant radiotherapy is recommended for incompletely excised and most invasive thymomas. Chemotherapy in anthracycline-based chemotherapy remains the most effective chemotherapy for neoadjuvant, adjuvant or palliative treatment.


Assuntos
Timoma/terapia , Neoplasias do Timo/terapia , Antineoplásicos/uso terapêutico , Quimioterapia Adjuvante , Humanos , Estadiamento de Neoplasias , Radioterapia Adjuvante , Timoma/diagnóstico , Timoma/patologia , Neoplasias do Timo/diagnóstico , Neoplasias do Timo/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA